

- Primary pigmented nodular adrenal disease (PPNAD), 2314, 2343
- Primary polydipsia, 2276, 2277, 2279
- Primary progressive aphasia, 2603. *See also* Frontotemporal dementia (FTD)
- Primary sclerosing cholangitis (PSC), **2061**
 cholangiocarcinoma and, 552
 clinical features of, 284, 1958, 2061, 2085–2086
 diagnosis of
 cholangiography in, 284, 1958, 2061–2062, 2079f, 2085–2086
 laboratory tests in, 1937, 2061
 liver biopsy in, 366e-5f
 diseases associated with, 2084–2085
 drug-induced, 2023
 in HIV infection, 2086
 in IBD, 1958
 IgG4-related, 391e-1, 391e-2. *See also* IgG4-related disease (IgG4-RD)
 natural history of, 2086
 small duct, 1958, 2086
 treatment of, 2062, 2068, 2086
- Primary sex headache, 2597
- Primary stabbing headache, 2597–2598
- Primary taste cortex (PTC), 214
- Primary thunderclap headache, 2597
- Primate immunodeficiency viruses, 1216, 1216f, 1219. *See also* HIV
- Primidone
 adverse effects of, 646t, 2554t
 for ataxia/tremor, 2620
 drug interactions of, 2554t
 for epilepsy, 2554t
 for myoclonus, 2623
 overdose/poisoning with, 473e-10t, 2765t
 therapeutic monitoring of, 2765t
- Priming, T cells, 103e-20
- Primitive neuroectodermal tumors (PNETs), 119e-4. *See also* Ewing's sarcoma
- Primitive reflexes, 2539
- Principal cells, 64e-2f, 304, 332e-5f, 332e-9
- Principal coordinates analysis, 86e-1t, 86e-3f, 86e-5
- PR interval, 273e-1
- Prinzmetal's variant angina, 1456, 1579, 1588, **1598**
- Prion(s)
 characteristics of, 214e-1
 decontamination of, 453e-5–6
 definition of, 453e-1, 453e-1t
 diseases due to. *See* Prion disease(s)
 strains of, 453e-2–3, 453e-2t
 structure of, 453e-1f
 terminology related to, 453e-1t
 transmissibility of, 453e-1–2
- Prion disease(s), **453e-1**
 classification of, 444e-10, 444e-12t
 clinical features of, 451e-2t
 Creutzfeldt-Jakob disease. *See* Creutzfeldt-Jakob disease
 epidemiology of, 453e-1t, 453e-2
 genetic considerations in, 451e-2t
 global considerations in, 453e-1–2, 453e-1t
 Huntington disease–like disorders, 2622
 inherited, 453e-3
 neurodegenerative, 444e-12t, 453e-6
 pathogenesis of, 444e-8f, 444e-10–11, 453e-1t, 453e-2–3, 453e-2f
 research in, 453e-6
 species barrier in, 453e-3
 sporadic, 453e-3
 types of, 453e-1–2, 453e-1t
- Prion proteins, 453e-1, 453e-1f, 453e-2t
- Prion rod, 453e-1t
- Pritelivir, 215e-9
- PRKAG2 deficiency, 433e-2t, 433e-5
- PRKAG2 gene mutations, 1566
- PRKARIA gene, 289e-1, 2266, 2314
- PRNP gene, 172t, 453e-1t, 453e-3, 2622
- Probenecid
 action of, 332e-8
 adverse effects of, 282
 for CMV infection prophylaxis in HIV infection, 1252t
- drug interactions of, 3, 42t, 103e-14, 246e-6t
 for gonococcal infections, 1009t
 for gout, 2234
 for neurosyphilis, 1139t
 for syphilitic meningitis, 899
- Probiotics, 263, 1970
- Procainamide
 action of, 273e-6t
 adverse effects of
 lupus syndrome, 40, 44, 2218t
 in myasthenia gravis, 2703
 myopathy, 462e-20, 2199
 nonarrhythmic, 1480t
 proarrhythmic, 1480t
 pure red cell aplasia, 668t
 thrombocytopenia, 727t
 for arrhythmias, 1479t
 for cardiac arrest, 1769f, 1770
 dosage of, 1479t
 genetic variations in response to, 39t, 40
 metabolism of, 34t, 35
 pharmacology of, 1479t
 for preexcited tachycardias, 1482
 for PSVT, 1483f
 therapeutic monitoring of, 2765t
 for ventricular arrhythmias, 1498
 for ventricular tachycardia, 1608
- Procalcitonin, 806
- Procarbazine
 action of, 103e-8, 103e-9t
 adverse effects of, 103e-9t
 gonadal dysfunction, 103e-25, 2365
 myelosuppression, 103e-23
 neurologic, 607t
 drug interactions of, 103e-9t
 for oligodendroglioma, 601
- Procaspase-9, 102e-9f
- Process (quality theory), 12e-2
- Prochlorperazine
 adverse effects of, 284
 for migraine, 2592, 2592t
 for nausea and vomiting, 61–62, 103e-25, 260t, 261, 474
 parenteral, 2592t
 for scambroid poisoning, 2744
- Procidencia. *See* Rectal prolapse
- Proctitis
C. trachomatis, 1168, 1169, 1170t
 HSV, 1178, 1182t, 1956
 sexually acquired, 870t, 881–882, 1005, 1168, 1169
 ulcerative colitis and, 1952
- Proctocolitis, sexually acquired, 881–882
- Proctopathy, radiation, 346e-1v
- Proctosigmoidoscopy. *See* Sigmoidoscopy
- Prodrugs, 35
- Progenitor cells, 89e-4f, 454
- Progeria, 435, 436t
- Progeroid syndromes, 94e-4
- Progesterone, 324, 2378, 2762t
- Progesterone receptors, 120e-2t, 528
- Progestins
 adverse effects of, 253t
 with estrogens, 2498
 in oral contraceptives, 2390–2391
 in perimenopause, 2382
 for polycystic ovarian syndrome, 337
 in postmenopausal hormone therapy. *See* Postmenopausal hormone therapy
- Progestogens, 530t
- Proglottids, 255e-1
- Prognathism, 237
- Program for All Inclusive Care of the Elderly (PACE), 82–83
- Programmed cell death. *See* Apoptosis
- Programmed death theory of aging, 94e-2
- Progranulin, 2603
- Progressive diaphyseal dysplasia (Camurati-Engelmann disease), 426e-5
- Progressive external ophthalmoplegia
 clinical features of, 41e-1v, 85e-6, 85e-6t, 207, 462e-15–16
 diagnosis of, 462e-15–16
- differential diagnosis of, 2703
 genetic considerations in, 85e-6, 85e-6t, 85e-7f, 462e-16
- Progressive familial intrahepatic cholestasis, 284, 2003t, 2004
- Progressive massive fibrosis, 1690
- Progressive multifocal leukoencephalopathy (PML), **899**
 in cancer patient, 488, 488t, 490
 clinical features of, 899
 diagnosis of, 899–900
 in HIV infection, 899–900, 1266
 monoclonal antibodies and, 372e-31, 1962, 2147, 2669
 pathology of, 899
 TNF- α inhibitors and, 348
 treatment of, 899–900
- Progressive muscular atrophy. *See* Spinal muscle atrophy (SMA)
- Progressive myoclonus epilepsy, 2545t
- Progressive myopathy, 436e-6f
- Progressive rubella panencephalitis, 900
- Progressive supranuclear palsy syndrome
 clinical features of, 173, 2604, 2612t
 eye movements in, 41e-1v, 2604, 2610
 falls in, 163, 165
 gait disorders in, 163, 2610
 neuropathology of, 2604–2605, 2604f, 2605f, 2610–2611
- Proguanil
 action of, 246e-12
 adverse effects of, 246e-4t, 1380t, 1384
 drug interactions of, 246e-4t
 for malaria, 1380t
 for malaria prophylaxis, 1382, 1383, 1383t, 1384
 pharmacology of, 246e-12, 1380t
 in pregnancy and lactation, 246e-4t, 1384
 resistance to, 1384
- Proinsulin, 2434
- Project BioShield, 261e-10
- PROK2 gene mutations, 2363, 2364t
- PROK2R gene mutations, 2363, 2364t
- Prokinetic agents, 260t, 263
- Prolactin, **401e-1**
 action of, 401e-3
 expression and regulation of, 401e-1t
 laboratory evaluation of, 2258t, 2762t
 secretion of, 401e-2
 synthesis of, 401e-1–2
- Prolactinoma, **2267**
 clinical features of, 2267
 diagnosis of, 2267
 etiology of, 2267
 in MEN 1, 2336t, 2339
 during pregnancy, 2268–2269
 prevalence of, 2267
 screening tests for, 2262t
 treatment of, 2267–2268, 2268f
- Prolidase deficiency, 434e-2t
- Proliferative inflammatory atrophy, of prostate, 580
- Proline metabolism disorders, 434e-2t, 434e-3t
- Polymorphocytic leukemia, 412
- Promethazine, 151t, 389t
- Prometrium, 337
- PROMM (proximal myotonic myopathy), 462e-3, 462e-9, 462e-10
- Promonocytes, 421
- Promoter (carcinogenesis), 476
- Promyelocytes, 414f, 415
- Promyelocytic leukemia. *See* Acute promyelocytic leukemia
- Pronator drift, 2538
- Pronormoblast, 392
- Pronormoblasts, giant, 668, 668f
- Proopiomelanocortin (POMC)
 deficiency, 2325t
 in obesity, 415e-3, 415e-4f, 415e-4t
- PROP-1
 in anterior pituitary development, 401e-1, 401e-1t, 2256
 in congenital hypothyroidism, 2284t
 in GH deficiency, 2258